Actuate Therapeutics, Inc. Common stock (ACTU)
Develops cancer drugs targeting pancreatic cancer and childhood tumors.
$1.06-0.08%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-85.4%
The outlook
ACTU is trading near its 52-week low at $1.06, well below both its 50- and 200-day moving averages. Analyst sentiment shows a stark disconnect: the average price target sits roughly 8x the current price, suggesting significant upside if targets materialize, though current analyst coverage appears limited and the overall score reflects bearish positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +841% vs current price
Analyst price target
~12-month · 4 analysts$9.98average target+841.3% vs now
Now $1.06
Low $5.00High $14.91
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$25.4M
52-wk high
$9.22
52-wk low
$1.03
50-day avg
$1.79
200-day avg
$4.10
Trailing P/E
—